AC Immune (ACIU) Other Non-Current Liabilities (2015 - 2016)
AC Immune (ACIU) posted quarterly Other Non-Current Liabilities of $9.4 million for Q4 2016, up 53.62% year-over-year from $6.1 million in Q1 2016, and up 8551.75% quarter-over-quarter from $108662.8 in Q3 2016.
AC Immune (ACIU) Other Non-Current Liabilities (2015 - 2016) Analysis & Trends
AC Immune (ACIU) has reported Other Non-Current Liabilities for 2 consecutive years, with $9.4 million the latest figure, recorded in Q4 2016.
- In Q4 2016, Other Non-Current Liabilities rose 53.62% year-over-year to $9.4 million; the TTM figure through Dec 2016 stood at $9.4 million (up 53.62% YoY), while the FY2016 annual figure was $9.5 million, up 51.62% from the prior year.
- Other Non-Current Liabilities rose to $9.4 million in Q4 2016 per ACIU's latest filing, from $108662.8 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $9.4 million in Q4 2016 and bottomed at $108662.8 in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 9.40 Mn |
| Sep 30, 2016 | 108,662.78 |
| Dec 31, 2015 | 6.12 Mn |